Gadofosveset

From Wikipedia, the free encyclopedia
Gadofosveset trisodium
Gadofosveset skeletal.svg
Clinical data
Trade namesVasovist, Ablavar
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
Identifiers
  • Trisodium 2-{[(2R)-2-[bis(2-oxido-2-oxoethyl)amino]-3-[(4,4-diphenylcyclohexyl)oxy-oxidophosphoryl]oxypropyl]-[2-[bis(2-oxido-2-oxoethyl)amino]ethyl]amino}acetate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC33H40GdN3Na3O15P
Molar mass975.88 g·mol−1
3D model (JSmol)
  • [Gd+3].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)C[C@@H](N(CC([O-])=O)CC([O-])=O)COP([O-])(=O)OC3CCC(c1ccccc1)(c2ccccc2)CC3.O
  • InChI=1S/C33H44N3O14P.Gd.3Na.H2O/c37-28(38)18-34(15-16-35(19-29(39)40)20-30(41)42)17-26(36(21-31(43)44)22-32(45)46)23-49-51(47,48)50-27-11-13-33(14-12-27,24-7-3-1-4-8-24)25-9-5-2-6-10-25;;;;;/h1-10,26-27H,11-23H2,(H,37,38)(H,39,40)(H,41,42)(H,43,44)(H,45,46)(H,47,48);;;;;1H2/q;+3;3*+1;/p-6/t26-;;;;;/m1...../s1
  • Key:PIZALBORPSCYJU-QSQMUHTISA-H

Gadofosveset (trade names Vasovist, Ablavar) is a gadolinium-based MRI contrast agent. It was used as the trisodium salt monohydrate form.[1][2] It acts as a blood pool agent by binding to human serum albumin. The manufacturer (Lantheus Medical) discontinued production in 2017 due to poor sales.[3]

Gadofosveset facilitates high-resolution magnetic resonance angiography.[4] Ferumoxytol (trade names Feraheme, Rienso), an intravenous iron-replacement therapy, has been shown to potentially be superior to gadofosveset as a blood pool agent for MR venography in pediatric patients.[5]

References[]

  1. ^ DailyMed: Vasovist
  2. ^ Drugs.com: Ablavar
  3. ^ Bell D, Morgan M. "Gadofosveset trisodium". Radiopaedia. radiopaedia.org. Retrieved 2018-08-28.
  4. ^ Sabach AS, Bruno M, Kim D, Mulholland T, Lee L, Kaura S, Lim RP (June 2013). "Gadofosveset trisodium: abdominal and peripheral vascular applications". AJR. American Journal of Roentgenology. 200 (6): 1378–86. doi:10.2214/AJR.12.8991. PMID 23701079.
  5. ^ Shahrouki P, Khan SN, Yoshida T, Iskander PJ, Ghahremani S, Finn JP (March 2022). "High-resolution three‑dimensional contrast‑enhanced magnetic resonance venography in children: comparison of gadofosveset trisodium with ferumoxytol". Pediatric Radiology. 52 (3): 501–512. doi:10.1007/s00247-021-05225-2. PMC 8857136. PMID 34936018.
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by .

  • v
  • t
Retrieved from ""